Bank of America Has Lowered Expectations for DaVita (NYSE:DVA) Stock Price

DaVita (NYSE:DVA) had its target price lowered by analysts at Bank of America from $145.00 to $140.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an “underperform” rating on the stock. Bank of America‘s price objective indicates a potential upside of 5.01% from the company’s current price.

Several other brokerages also recently weighed in on DVA. Truist Financial set a $148.00 price objective on DaVita in a research report on Friday, August 8th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Friday, August 22nd. Finally, Barclays cut their price objective on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, DaVita presently has a consensus rating of “Reduce” and an average target price of $158.00.

DaVita Price Performance

Shares of DaVita stock opened at $133.32 on Wednesday. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18. The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of 13.11, a price-to-earnings-growth ratio of 0.95 and a beta of 1.13. The company has a 50-day simple moving average of $138.64 and a two-hundred day simple moving average of $141.60. DaVita has a twelve month low of $126.07 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the prior year, the business posted $2.00 earnings per share. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Analysts forecast that DaVita will post 10.76 EPS for the current year.

Insider Activity at DaVita

In other DaVita news, insider James O. Hearty sold 2,351 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares of the company’s stock, valued at $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.50% of the company’s stock.

Institutional Trading of DaVita

Institutional investors and hedge funds have recently bought and sold shares of the company. UMB Bank n.a. boosted its stake in DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $29,000 after buying an additional 76 shares during the period. National Pension Service boosted its stake in shares of DaVita by 74.3% during the first quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after purchasing an additional 84 shares during the period. Copia Wealth Management purchased a new position in shares of DaVita in the fourth quarter valued at about $30,000. Hantz Financial Services Inc. raised its position in DaVita by 48.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Y.D. More Investments Ltd purchased a new stake in DaVita in the first quarter worth $35,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.